Ernexa Therapeutics Inc. (NASDAQ:ERNA) Short Interest Update

Ernexa Therapeutics Inc. (NASDAQ:ERNA) saw a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 247,054 shares, a growth of 136.9% from the February 12th total of 104,299 shares. Currently, 3.3% of the company’s shares are sold short. Based on an average daily trading volume, of 4,663,750 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 4,663,750 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.3% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 70.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Ernexa Therapeutics has a consensus rating of “Sell”.

Ernexa Therapeutics Stock Up 4.9%

Shares of Ernexa Therapeutics stock opened at $0.32 on Friday. The stock’s fifty day moving average is $0.73 and its two-hundred day moving average is $1.12. The company has a market capitalization of $2.54 million, a PE ratio of -0.11 and a beta of 6.58. Ernexa Therapeutics has a 52 week low of $0.27 and a 52 week high of $4.20.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.